Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
Thirty-four patients with advanced malignant melanoma received AZQ (an aziridinylbenzoquinone) at a dose of 22.5 or 27.5 mg/m2/month iv. Objective regressions among 23 previously untreated and 11 previously treated patients were two and none, respectively. Hematologic toxicity was dose-limiting.
D001388:Aziridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D016227:Benzoquinones; D053138:Cyclohexenes; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000188:drug therapy*
D001388:Aziridines; D001389:Azirines; D016227:Benzoquinones; D053138:Cyclohexenes; C006052:2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone